UFP Energy, Environment and Health Research Unit (FP-ENAS), Fernando Pessoa University, Porto, Portugal.
UCIBIO, ReQuimTe, Laboratory of Pharmaceutical Technology/Centre of Research in Pharmaceutical Sciences, Faculty of Pharmacy, Porto University, Porto, Portugal.
Eur J Pharm Sci. 2018 Jan 15;112:159-167. doi: 10.1016/j.ejps.2017.11.023. Epub 2017 Nov 26.
Cutaneous use of lipid nanoparticles (solid lipid nanoparticles, SLN and nanostructured lipid carriers, NLC) has been showing promising results. These systems consist of low viscosity aqueous dispersions, being usually employed by means of semi-solid formulations with adequate consistency for skin application. This review addresses the cutaneous use of lipid nanoparticles for therapeutic and cosmetic applications. Initially, general information related to pharmaceutical semi-solid formulations is presented. Afterwards, the effects of SLN and NLC on the skin, and technological aspects related to semi-solid systems based on SLN or NLC are described. Finally, the most relevant studies related to the formulations based on SLN and NLC, for cosmetic and therapeutic applications, are reported. Notwithstanding the cutaneous use of SLN and NLC has been proposed for both local and transdermal delivery, the reported studies show promising results only for local application. In this sense, more research is required to better understanding the interaction mechanisms of lipid nanoparticles with skin lipids. Furthermore, the development of standard methods for skin experiments with nanoparticles is necessary.
经皮使用脂质纳米粒(固体脂质纳米粒,SLN 和纳米结构脂质载体,NLC)已显示出良好的效果。这些系统由低粘度的水相分散体组成,通常通过具有适当稠度的半固体制剂来使用,以适用于皮肤应用。本综述介绍了脂质纳米粒在治疗和美容应用中的经皮使用。首先,介绍了与药物半固体制剂相关的一般信息。然后,描述了 SLN 和 NLC 对皮肤的影响,以及基于 SLN 或 NLC 的半固体系统的技术方面。最后,报告了与 SLN 和 NLC 制剂相关的最相关的研究,这些制剂用于美容和治疗应用。尽管已经提出将 SLN 和 NLC 用于局部和经皮给药,但报告的研究仅显示出局部应用的有前景的结果。在这方面,需要进行更多的研究以更好地理解脂质纳米粒与皮肤脂质的相互作用机制。此外,有必要开发用于纳米粒子皮肤实验的标准方法。
Adv Drug Deliv Rev. 2002-11-1
Expert Opin Drug Deliv. 2020-2-17
Pharm Dev Technol. 2013-3-26
AAPS PharmSciTech. 2025-8-8
Naunyn Schmiedebergs Arch Pharmacol. 2025-4-25
Adv Pharm Bull. 2024-12-30
Ther Deliv. 2025-3
Pharmaceuticals (Basel). 2025-2-4
Int J Nanomedicine. 2025-2-19